FDA Warning To Skin Care Firm Shows Perils Of Cosmetics-To-OTC Transition
This article was originally published in The Tan Sheet
Executive Summary
FDA's warning letter saying skin care product firm MW Laboratories marketed unapproved new drugs illustrates the potentially perilous transition from offering cosmeceuticals to marketing OTC drugs